About

Srinivas Akkaraju, MD, PhD

Srinivas Akkaraju, MD, PhD

Chairman

Srinivas Akkaraju, MD, PhD

Srini Akkaraju has more than 20 years of investment and operational experience in the life sciences sector. Since 2016, he has been the Managing General Partner at Samsara BioCapital, a venture fund focused on biopharmaceutical investments.
From April 2013 until June 2016, he was a Managing General Partner with Sofinnova Ventures. Srini’s board memberships have included ZS Pharma (acquired by AstraZeneca),  Eyetech Pharmaceuticals (EYET), Synageva BioPharma (GEVA), Seattle Genetics (SGEN) and Intercept Pharmaceuticals (ICPT). Previously, Srini served as a Managing Director at New Leaf Venture Partners and was a Managing Director at Panorama Capital. Before forming Panorama, he served as Partner of J.P. Morgan Partners. Prior to J.P. Morgan Partners, Srini held business and corporate development positions at Genentech. He received BA degrees in both Biochemistry and Computer Science from Rice University and MD and PhD degrees in Immunology from Stanford University School of Medicine.